By inhibiting activated γ9δ2 T cells, our anti-BTN3A antagonist may shutdown dysfunctional activation associated with autoimmune disease.
ImCheck Therapeutics is collaborating with world-class academic centers that have strong experience in AID including inflammatory bowel disease and rheumatic diseases, in order to better understand the pathophysiologic roles of γ9δ2 T cells and the therapeutic potential of ICT21.
Mechanism of action
